{
  "version": "1.0.0",
  "lastUpdated": "2025-01-15",
  "description": "Evidence-based Treatment Plan Generator Rules for MHT Assessment",
  "guidelines": {
    "NICE": "https://www.nice.org.uk/guidance/ng23",
    "ACOG": "https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2014/01/hormone-therapy-and-heart-disease",
    "EndocrineSociety": "https://www.endocrine.org/clinical-practice-guidelines",
    "IMS": "https://www.imsociety.org/manage/guidelines/"
  },
  "riskThresholds": {
    "ascvd": {
      "low": 5,
      "moderate": 10,
      "high": 20
    },
    "framingham": {
      "low": 10,
      "moderate": 20,
      "high": 30
    },
    "wells": {
      "low": 1,
      "moderate": 3,
      "high": 6
    },
    "frax": {
      "majorFracture": {
        "low": 10,
        "moderate": 15,
        "high": 20
      },
      "hipFracture": {
        "low": 3,
        "moderate": 5,
        "high": 10
      }
    },
    "gail": {
      "low": 1.67,
      "moderate": 2.5,
      "high": 3.5
    }
  },
  "absoluteContraindications": [
    {
      "id": "active_breast_cancer",
      "condition": "personalHistoryBreastCancer",
      "value": true,
      "rule": "RULE_001",
      "severity": "absolute",
      "recommendation": "Do not start systemic HRT",
      "alternatives": ["vaginal_estrogen", "ssri_snri", "cbt", "lifestyle"],
      "rationale": "Active or recent breast cancer is an absolute contraindication to systemic HRT",
      "guidelines": ["NICE", "ACOG", "EndocrineSociety"],
      "references": ["NICE NG23 1.4.1", "ACOG Committee Opinion 565"]
    },
    {
      "id": "active_vte",
      "condition": "personalHistoryDVT",
      "value": true,
      "rule": "RULE_002",
      "severity": "absolute",
      "recommendation": "Do not start systemic HRT - consider alternatives",
      "alternatives": ["vaginal_estrogen", "ssri_snri", "clonidine", "lifestyle"],
      "rationale": "Active or recent VTE is an absolute contraindication to systemic HRT",
      "guidelines": ["NICE", "ACOG"],
      "references": ["NICE NG23 1.4.2", "ACOG Practice Bulletin 141"]
    },
    {
      "id": "unexplained_bleeding",
      "condition": "unexplainedVaginalBleeding",
      "value": true,
      "rule": "RULE_003",
      "severity": "absolute",
      "recommendation": "Investigate unexplained bleeding before considering HRT",
      "alternatives": ["bleeding_investigation"],
      "rationale": "Unexplained vaginal bleeding requires investigation before HRT initiation",
      "guidelines": ["NICE", "ACOG"],
      "references": ["NICE NG23 1.4.3"]
    },
    {
      "id": "active_liver_disease",
      "condition": "liverDisease",
      "value": true,
      "rule": "RULE_004",
      "severity": "absolute",
      "recommendation": "Do not start HRT with active liver disease",
      "alternatives": ["liver_assessment", "non_hormonal"],
      "rationale": "Active liver disease is a contraindication to HRT",
      "guidelines": ["NICE"],
      "references": ["NICE NG23 1.4.4"]
    }
  ],
  "relativeContraindications": [
    {
      "id": "high_ascvd_risk",
      "conditions": [
        {"field": "ascvdResult.tenYearRisk", "operator": ">", "value": 20}
      ],
      "rule": "RULE_101",
      "severity": "high",
      "recommendation": "Consider alternatives to systemic HRT due to high cardiovascular risk",
      "alternatives": ["transdermal_hrt", "ssri_snri", "lifestyle", "cardiology_consult"],
      "rationale": "ASCVD risk >20% suggests increased cardiovascular risk with systemic HRT",
      "guidelines": ["ACOG", "EndocrineSociety"],
      "references": ["ACOG Committee Opinion 565"],
      "monitoring": "Cardiology evaluation recommended"
    },
    {
      "id": "high_wells_score",
      "conditions": [
        {"field": "wellsScore", "operator": ">=", "value": 6}
      ],
      "rule": "RULE_102",
      "severity": "high",
      "recommendation": "High VTE risk - avoid oral HRT, consider transdermal if appropriate",
      "alternatives": ["transdermal_hrt", "vaginal_estrogen", "ssri_snri"],
      "rationale": "High Wells score indicates elevated VTE risk with oral HRT",
      "guidelines": ["NICE"],
      "references": ["NICE NG23 1.5.2"],
      "monitoring": "Consider thrombophilia screening"
    },
    {
      "id": "smoking_over_35",
      "conditions": [
        {"field": "smoking", "operator": "==", "value": true},
        {"field": "age", "operator": ">", "value": 35}
      ],
      "rule": "RULE_103",
      "severity": "moderate",
      "recommendation": "Smoking increases HRT risks - prioritize smoking cessation",
      "alternatives": ["smoking_cessation", "transdermal_hrt", "non_hormonal"],
      "rationale": "Smoking combined with HRT increases cardiovascular and VTE risks",
      "guidelines": ["NICE", "ACOG"],
      "references": ["NICE NG23 1.5.3"],
      "monitoring": "Smoking cessation support essential"
    },
    {
      "id": "high_frax_score",
      "conditions": [
        {"field": "fraxResult.majorFractureRisk", "operator": ">", "value": 20}
      ],
      "rule": "RULE_104",
      "severity": "low",
      "recommendation": "Consider HRT benefits for bone protection in high fracture risk",
      "alternatives": ["hrt_for_bones", "bisphosphonates", "denosumab"],
      "rationale": "High FRAX score may justify HRT for bone protection benefits",
      "guidelines": ["EndocrineSociety", "IMS"],
      "references": ["Endocrine Society Clinical Practice Guideline"],
      "monitoring": "Bone density monitoring recommended"
    }
  ],
  "primaryRecommendations": [
    {
      "id": "low_risk_severe_symptoms",
      "conditions": [
        {"field": "ascvdResult.tenYearRisk", "operator": "<=", "value": 10},
        {"field": "wellsScore", "operator": "<=", "value": 2},
        {"field": "personalHistoryBreastCancer", "operator": "==", "value": false},
        {"field": "personalHistoryDVT", "operator": "==", "value": false},
        {"field": "vasomotorSymptoms", "operator": "in", "value": ["moderate", "severe"]}
      ],
      "rule": "RULE_201",
      "severity": "preferred",
      "recommendation": "Consider systemic HRT - lowest effective dose, shortest duration",
      "details": {
        "firstLine": "Oral estradiol with progestogen (if uterus present) OR transdermal estradiol",
        "dosing": "Start with lowest effective dose - estradiol 1mg daily or 25-50mcg patch",
        "duration": "Review annually, consider duration vs benefits",
        "route": "Oral or transdermal - patient preference and risk factors"
      },
      "alternatives": ["transdermal_hrt", "vaginal_estrogen", "ssri_snri"],
      "rationale": "Low risk profile with significant symptoms supports HRT as first-line therapy",
      "guidelines": ["NICE", "ACOG", "IMS"],
      "references": ["NICE NG23 1.2.1", "IMS Global Consensus Statement"],
      "monitoring": "Baseline: BP, BMI, breast exam. Follow-up: 3 months, then annually"
    },
    {
      "id": "moderate_risk_moderate_symptoms",
      "conditions": [
        {"field": "ascvdResult.tenYearRisk", "operator": "<=", "value": 15},
        {"field": "wellsScore", "operator": "<=", "value": 3},
        {"field": "age", "operator": "<=", "value": 60},
        {"field": "vasomotorSymptoms", "operator": "in", "value": ["moderate"]}
      ],
      "rule": "RULE_202",
      "severity": "consider",
      "recommendation": "HRT may be considered with enhanced monitoring",
      "details": {
        "firstLine": "Transdermal estradiol preferred to minimize VTE risk",
        "dosing": "Conservative dosing - estradiol 25mcg patch twice weekly",
        "duration": "Limit duration, review every 6 months",
        "route": "Transdermal preferred over oral"
      },
      "alternatives": ["ssri_snri", "vaginal_estrogen", "lifestyle"],
      "rationale": "Moderate risk requires careful risk-benefit assessment",
      "guidelines": ["NICE", "ACOG"],
      "references": ["NICE NG23 1.2.2"],
      "monitoring": "Enhanced monitoring: 3 months, 6 months, then 6-monthly"
    },
    {
      "id": "low_risk_mild_symptoms",
      "conditions": [
        {"field": "ascvdResult.tenYearRisk", "operator": "<=", "value": 10},
        {"field": "vasomotorSymptoms", "operator": "==", "value": "mild"}
      ],
      "rule": "RULE_203",
      "severity": "alternative",
      "recommendation": "Consider non-hormonal options first for mild symptoms",
      "details": {
        "firstLine": "Lifestyle modifications, SSRIs/SNRIs, or CBT",
        "secondLine": "HRT if non-hormonal options ineffective",
        "approach": "Step-wise approach starting with lowest-risk options"
      },
      "alternatives": ["lifestyle", "ssri_snri", "cbt", "systemic_hrt"],
      "rationale": "Mild symptoms may respond to lower-risk interventions",
      "guidelines": ["NICE"],
      "references": ["NICE NG23 1.1.1"],
      "monitoring": "Symptom assessment at 6-8 weeks, consider HRT if inadequate response"
    }
  ],
  "alternativeTreatments": {
    "vaginal_estrogen": {
      "name": "Vaginal Estrogen",
      "indication": "Genitourinary symptoms, safe with contraindications",
      "dosing": "Estradiol vaginal tablets 10mcg daily for 2 weeks, then twice weekly",
      "benefits": "Minimal systemic absorption, effective for urogenital symptoms",
      "risks": "Minimal systemic effects, local irritation possible",
      "monitoring": "Annual review, no routine endometrial monitoring needed"
    },
    "ssri_snri": {
      "name": "SSRIs/SNRIs",
      "indication": "Vasomotor symptoms when HRT contraindicated",
      "options": "Paroxetine 7.5mg, Venlafaxine XR 37.5-75mg, Citalopram 10-20mg",
      "benefits": "No cancer or VTE risk, may help mood symptoms",
      "risks": "Sexual dysfunction, GI effects, drug interactions",
      "monitoring": "2-4 week review, then 3-monthly"
    },
    "clonidine": {
      "name": "Clonidine",
      "indication": "Vasomotor symptoms, particularly when HRT contraindicated",
      "dosing": "50-75mcg twice daily, maximum 150mcg twice daily",
      "benefits": "No hormonal effects, may help sleep",
      "risks": "Hypotension, dry mouth, sedation, rebound hypertension",
      "monitoring": "BP monitoring essential, gradual withdrawal required"
    },
    "lifestyle": {
      "name": "Lifestyle Modifications",
      "indication": "All patients, particularly mild symptoms",
      "interventions": "Weight management, regular exercise, smoking cessation, stress reduction",
      "benefits": "Overall health benefits, no medication risks",
      "evidence": "Moderate evidence for symptom improvement",
      "monitoring": "Ongoing support and review"
    },
    "cbt": {
      "name": "Cognitive Behavioral Therapy",
      "indication": "Psychological symptoms, hot flashes",
      "approach": "Structured CBT program for menopause symptoms",
      "benefits": "Addresses psychological aspects, no medication risks",
      "evidence": "Good evidence for hot flash reduction and mood improvement",
      "monitoring": "Regular sessions with trained therapist"
    },
    "bisphosphonates": {
      "name": "Bisphosphonates",
      "indication": "Osteoporosis prevention/treatment",
      "options": "Alendronate 70mg weekly, Risedronate 35mg weekly",
      "benefits": "Proven fracture reduction, no cancer risk",
      "risks": "GI intolerance, osteonecrosis of jaw (rare), atypical fractures",
      "monitoring": "Annual bone density, dental assessment"
    }
  },
  "monitoringProtocols": {
    "baseline_hrt": {
      "name": "Baseline Assessment for HRT",
      "timepoint": "Before HRT initiation",
      "assessments": [
        "Blood pressure measurement",
        "BMI calculation",
        "Breast examination",
        "Cervical screening if due",
        "Family history review",
        "Baseline symptom assessment"
      ],
      "optional": [
        "Mammography if overdue",
        "Bone density if indicated",
        "Lipid profile if cardiovascular risk factors",
        "LFTs if liver concerns"
      ]
    },
    "early_followup": {
      "name": "Early Follow-up",
      "timepoint": "3 months after HRT initiation",
      "assessments": [
        "Symptom response assessment",
        "Side effect evaluation",
        "Blood pressure check",
        "Adherence review",
        "Dose adjustment if needed"
      ]
    },
    "annual_review": {
      "name": "Annual Review",
      "timepoint": "Annually while on HRT",
      "assessments": [
        "Comprehensive symptom assessment",
        "Risk-benefit reassessment",
        "Blood pressure and BMI",
        "Breast examination",
        "Mammography as per guidelines",
        "Duration of therapy review"
      ]
    }
  },
  "patientCounseling": {
    "hrt_benefits": [
      "Effective relief of vasomotor symptoms (hot flashes, night sweats)",
      "Improvement in sleep quality and mood",
      "Prevention of bone loss and fracture risk reduction",
      "Improvement in genitourinary symptoms",
      "Potential cardiovascular benefits if started early"
    ],
    "hrt_risks": [
      "Small increased risk of breast cancer with long-term use",
      "Increased risk of VTE, particularly with oral preparations",
      "Possible increased stroke risk in older women",
      "Return of menstrual bleeding with some regimens",
      "Breast tenderness and mood changes possible"
    ],
    "shared_decision_points": [
      "Individual risk-benefit profile varies significantly",
      "Lowest effective dose for shortest duration principle",
      "Regular review and reassessment essential",
      "Alternative treatments available if HRT unsuitable",
      "Patient preferences and values crucial in decision-making"
    ]
  }
}